LungLife AI, INC Block listing Interim Review
15 Novembre 2024 - 8:00AM
RNS Regulatory News
RNS Number : 7676L
LungLife AI, INC
15 November 2024
LungLife AI, Inc.
(the "Company" or
"LungLife")
Block Listing Six Monthly
Return
LungLife AI (AIM: LLAI), a developer of
clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing
pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for
Companies:
|
Name of applicant:
|
LungLife AI, Inc.
|
|
Name of scheme:
|
1. 2010 Stock
Incentive Plan
2. 2020 Stock
Incentive Plan
3. 2021 Omnibus
Long-Term Incentive Plan
|
|
Number and class of securities
originally admitted:
|
1,356,139 common shares of US
$0.0001 each
|
|
Date of admission:
|
15 November 2021
|
|
Period of return:
|
From:
|
15 May 2024
|
To:
|
15 November 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
1.
475,583
2.
201,374
3.
673,990
|
|
Plus: The amount by which the block
scheme(s) has been increased since the date of the last return (if
any increase has been applied for):
|
1. NIL
2. NIL
3. NIL
|
|
Less: Number of securities
issued/allotted under scheme(s) during period (see
LR3.5.7G):
|
1. NIL
2. NIL
3. NIL
|
|
Equals: Balance under scheme(s) not
yet issued/allotted at end of period:
|
1.
475,583
2.
201,374
3.
673,990
|
|
Total number
of securities in issue at the end of the
period
|
30,658,603
|
|
|
|
|
| |
|
Name of contact:
|
David Anderson, Chief Financial
Officer
|
|
Telephone number of
contact:
|
+44 (0)20 7933 8780
|
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
via investors@lunglifeai.com
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser &
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Lydia Zychowska / Sara
Wallace
|
|
|
|
|
|
Goodbody
(Joint Broker)
|
Tel: +44 (0)20 3841
6202
|
|
Tom Nicholson / Cameron Duncan
|
|
|
|
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the
early detection to lung cancer. And our Vision is to invert
the 20:80 ratio such that in years to come at least 80% of lung
cancer is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRFLFIRLTLLLIS
Grafico Azioni Lunglife Ai (LSE:LLAI)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Lunglife Ai (LSE:LLAI)
Storico
Da Nov 2023 a Nov 2024
